Inventor · disambiguated record
Tammy T. Huang
Also filed as: HUANG TAMMY · HUANG TAMMY T
34 granted patents·19 pending applications·1,948 citations·filing 2007–2025
98Inventor score
Top patents by PatentIndex Score
53 records- 0199US8735095B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2012·Granted May 27, 2014·103 cites·29 claims
- 0299US8043617B2Human antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2009·Granted Oct 25, 2011·91 cites·9 claims
- 0399US7608693B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2008·Granted Oct 27, 2009·158 cites·10 claims
- 0499US7582298B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2007·Granted Sep 1, 2009·390 cites·7 claims
- 0598US9550837B2Therapeutic uses of anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2015·Granted Jan 24, 2017·31 cites·10 claims
- 0698US8501184B2High affinity human antibodies to PCSK9SLEEMAN MARK W·Filed 2010·Granted Aug 6, 2013·76 cites·3 claims
- 0798US8357371B2Methods for treating hypercholesterolemia using antibodies to PCSK9REGENERON PHARMA·Filed 2011·Granted Jan 22, 2013·89 cites·16 claims
- 0898US8062640B2High affinity human antibodies to PCSK9SLEEMAN MARK W·Filed 2009·Granted Nov 22, 2011·237 cites·3 claims
- 0997US10975139B1Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Apr 13, 2021·15 cites·20 claims
- 1097US10954289B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Mar 23, 2021·28 cites·28 claims
- 1197US10787501B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Sep 29, 2020·224 cites·20 claims
- 1297US8337839B2High affinity human antibodies to human IL-4 receptorMARTIN JOEL H·Filed 2011·Granted Dec 25, 2012·39 cites·5 claims
- 1397US8075887B2High affinity human antibodies to human IL-4 receptorMARTIN JOEL H·Filed 2009·Granted Dec 13, 2011·42 cites·5 claims
- 1497US7605237B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2007·Granted Oct 20, 2009·194 cites·6 claims
- 1596US12269897B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2023·Granted Apr 8, 2025·1 cites·12 claims
- 1696US10941210B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2018·Granted Mar 9, 2021·6 cites·8 claims
- 1796US10023654B2Anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2016·Granted Jul 17, 2018·16 cites·18 claims
- 1896US9884916B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2016·Granted Feb 6, 2018·13 cites·7 claims
- 1994US9724411B2Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9REGENERON PHARMA·Filed 2013·Granted Aug 8, 2017·15 cites·32 claims
- 2094US8338135B2High affinity human antibodies to human IL-4 receptorSTEVENS SEAN·Filed 2011·Granted Dec 25, 2012·33 cites·12 claims
- 2194US8192741B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyRADIN ALLEN·Filed 2011·Granted Jun 5, 2012·22 cites·10 claims
- 2294US8092802B2High affinity human antibodies to human IL-4 receptorSTEVENS SEAN·Filed 2010·Granted Jan 10, 2012·33 cites·4 claims
- 2394US7794717B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2009·Granted Sep 14, 2010·34 cites·4 claims
- 2493US11732030B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·51 claims
- 2593US8568721B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyRADIN ALLEN·Filed 2012·Granted Oct 29, 2013·18 cites·9 claims
- 2693US2025206829A1High affinity antibodies to human il-6 receptorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2792US8183014B2High affinity antibodies to human IL-6 receptorSTEVENS SEAN·Filed 2011·Granted May 22, 2012·11 cites·19 claims
- 2891US9308256B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyREGENERON PHARMA·Filed 2013·Granted Apr 12, 2016·11 cites·14 claims
- 2991US8080248B2Method of treating rheumatoid arthritis with an IL-6R antibodyRADIN ALLEN·Filed 2010·Granted Dec 20, 2011·15 cites·11 claims
- 3089US2025340672A1Vl antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3186US12251440B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·16 claims
- 3286US11370843B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2020·Granted Jun 28, 2022·1 cites·15 claims
- 3386US2024124613A1Vl antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3483US2023094591A1High affinity antibodies to human il-6 receptorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3579US2025154286A1Anti-pcsk9 antibodiesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3677US2021253735A1Anti-pcsk9 antibodiesREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3776US12162943B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2020·Granted Dec 10, 2024·0 cites·12 claims
- 3872US10584173B2Nucleic acids encoding high affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2018·Granted Mar 10, 2020·0 cites·15 claims
- 3972US2020377618A1Vl antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4071US2025197516A1High affinity human antibodies to human il-4 receptorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4170US10787522B2VL antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2018·Granted Sep 29, 2020·0 cites·20 claims
- 4269US12325752B2Immunoglobulin proteins that bind to NPR1 agonistsREGENERON PHARMA·Filed 2021·Granted Jun 10, 2025·0 cites·44 claims
- 4367US2014255995A1High affinity antibodies to human il-6 receptorREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4466US2024158515A1Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4566US2018179288A1High affinity human antibodies to human il-4 receptorREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 4665US2024173426A1Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4765US2014271681A1High Affinity Human Antibodies to Human IL-4 ReceptorREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4865US2025333524A1Immunoglobulin proteins that bind to npr1 agonistsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4964US2013085266A1ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICSREGENERON PHARMA·Filed 2012·Application pending·0 cites
- 5063US2013157313A1High affinity antibodies to human il-6 receptorSTEVENS SEAN·Filed 2012·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tammy T. Huang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →